Spironolactone in Covid-19 Induced ARDS

Completed

• Conditions: Respiratory Distress Syndrome, Adult
• Interventions: Drug: Spironolactone 100mg; Drug: Placebo oral tablet

• Registration Number: NCT04345887
• Lead Sponsor: Istanbul University - Cerrahpasa (IUC)

Brief Summary

This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-04-10
• Study First Submitted QC: 2020-04-10
• Study First Posted: 2020-04-15
• Study Start: 2020-05-05
• Primary Completion: 2020-06-15
• Study Completion: 2020-07-05
• Status Verified: 2021-10
• Last Update Submitted: 2021-10-21
• Last Update Posted: 2021-10-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Hemodynamically stable
• Hypoxemia, i.e. p/f <150
• Admitted to ICU within 48 hours
• Not moribund has a life expectancy greater than 24 hours

Exclusion Criteria

• Age criteria
• Pregnancy
• Unwillingness to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Spironolactone	Spironolactone 100mg	2 x 100 mg spironolactone
Placebo	Placebo oral tablet	2 x 1 placebo

Primary Outcome Measures

Name	Time	Method
p/f ratio	5 days	improvement in oxygenation

Secondary Outcome Measures

Name	Time	Method
SOFA	5 days	improvement in SOFA Score

Trial Locations

Locations (1)

Istanbul University-Cerrahpaşa; 🇹🇷 Istanbul, Turkey